Vectus Biosystems Ltd
VBS
Company Profile
Business description
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
Contact
26-34 Dunning Avenue
Unit 5, Ground Floor
Rosebery
SydneyNSW2018
AUST: +61 283441300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
There are 3 good reasons to buy this US dividend stock today
It’s a dividend aristocrat with a healthy yield that looks significantly undervalued even after its recent rally.
stocks
Strategic reset for ASX listed share
The global search for a new CEO is over, ending investor concern about leadership uncertainty.
stocks
ASX listed bank overvalued after shares surge
Investors were pleased with results but our fair value estimate is unchanged.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,163.80 | 5.80 | -0.06% |
| CAC 40 | 8,332.07 | 20.33 | 0.24% |
| DAX 40 | 25,001.32 | 86.44 | 0.35% |
| Dow JONES (US) | 49,497.29 | 45.31 | 0.09% |
| FTSE 100 | 10,471.53 | 25.18 | 0.24% |
| HKSE | 26,705.94 | 138.82 | 0.52% |
| NASDAQ | 22,546.67 | 50.48 | -0.22% |
| Nikkei 225 | 56,806.41 | 135.56 | -0.24% |
| NZX 50 Index | 13,117.91 | 80.27 | -0.61% |
| S&P 500 | 6,840.79 | 8.03 | 0.12% |
| S&P/ASX 200 | 8,937.10 | 8.30 | -0.09% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |